COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences
27/08/2025
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
27/08/2025
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on [...]
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
27/08/2025
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the [...]
Mesoblast Financial Results and Corporate Update Webcast
27/08/2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
27/08/2025
BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Voting Rights and Shares Capital of the Company
27/08/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
27/08/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 27 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
27/08/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases [...]
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
27/08/2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 Halle (Saale) / Munich, Germany, August 27 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
Idorsia successfully completes convertible bonds restructuring
27/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 27, 2025 Idorsia Ltd (SIX: IDIA) settled the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 ( CB 2025 [...]
Immuron partners with InvestorHub
27/08/2025
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides [...]
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
27/08/2025
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
27/08/2025
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) ( [...]
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
27/08/2025
LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Dentsply Sirona to Participate in Upcoming Investor Conferences
26/08/2025
CHARLOTTE, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Morgan Stanley 23 rd Annual Global [...]
Inspire Medical Systems, Inc. Announces Departure of Chief Financial Officer
26/08/2025
MINNEAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
SRx Health Solutions Announces Receipt of Late Filing Notification Letter from NYSE American
26/08/2025
TAMPA, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced that on August 20, 2025, it received an [...]
LifeStance to Present at the 23rd Annual Morgan Stanley Healthcare Conference
26/08/2025
SCOTTSDALE, Ariz., Aug. 26, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at [...]
Vera Therapeutics to Participate at Upcoming Investor Conferences
26/08/2025
BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]

Pages